虹桥商务区具备大交通、大会展、大商务、大科创四大功能，以及区位、政策、国际资源、人才四大独 特优势。 作为"十五五"规划的开局之年，融中第十五届中国资本年会暨大虹桥科创投资大会应势启幕。2026年1 月13日的大会上，上海虹桥国际中央商务区管委会党组书记、常务副主任孔福安发表了致辞。 孔福安介绍，虹桥商务区是服务企业"走出去"先行区与长三角企业"走出去"服务第一站，正着力构筑出 海企业总部高地、海外综合服务高地和出海制度创新高地。 孔福安表示，虹桥是长三角经济地理中心，1—2小时可覆盖长三角主要城市，依托长三角世界第三大经 济体的体量优势，新兴产业领域产业链完整。作为上海"两翼齐飞"的西翼和双向开放枢纽门户，既是国 内大循环中心节点，也是国内国际双循环战略链接，依托中国国际进口博览会等重大战略功能，助力其 向世界分享中国市场。 虹桥商务区具备大交通、大会展、大商务、大科创四大功能，以及区位、政策、国际资源、人才四大独 特优势。孔福安进一步介绍，虹桥重点发展总部、服务、会展、贸易四大经济，产业布局紧扣绿色低碳 转型、数字化转型、消费转型三大方向，时尚新消费、低碳新能源、数字新经济、生命新科技、汽车新 势力等领域 ...

缘起黄浦：平台聚力，共筑合作生态圈 专家论道：多维解读赴港上市核心要点 核心分享环节，三位行业专家分别从政策、法律与企业实践角度，提供了实用的赴港上市指南，帮助科技企业厘清思路、应对挑战。 科技企业出海上市，是链接全球资本、拓展国际市场的关键步伐。香港作为联通内地与世界的"超级联系人"，正日益成为科技企业汇聚的核心资本高地。 日前，由麻省理工学院上海校友会与港大上海校友会联合主办，黄浦海外联谊会鼎力支持的"科技与资本沙龙"在外滩FTC举行，汇聚沪港澳高校校友及政 策、法律、投资等多领域专家，通过主题分享、圆桌对话等形式，为企业打通政策解读、实务指导与资源对接的"最后一公里"，共探科技与资本融合的新 机遇。 本次沙龙聚焦"企业赴港上市"，从政策环境、科技企业实践、上市与出海战略等多个维度，帮助企业主系统理解香港市场的最新变化与关键机遇。 上海黄浦港澳联会会长叶向德在致辞中介绍了黄浦的区位优势，希望继续凝聚彼此的力量，把握当下的契机，共同书写沪港澳合作共赢的崭新篇章，为黄 浦增添更加璀璨的国际化光彩。 沙龙现场，麻省理工学院上海校友会会长高源表示，希望通过活动为校友企业搭建对接全球资本的桥梁；港大上海校友会副会长 ...

Group 1 - The event "Investment Qilu, Win the Future" focused on high-quality development and capital matching, attracting 7 national funds, 5 major AICs, and 117 domestic private equity investment institutions and financial representatives, totaling 380 participants [1] - A total of 150 quality investment projects from Shandong Province were promoted, covering strategic emerging industries such as artificial intelligence, high-end equipment manufacturing, new energy materials, and biomedicine, showcasing Shandong's solid foundation and broad space for industrial transformation and upgrading [1] - The event resulted in 37 funds and 13 key projects successfully landing in Shandong, with a total signed scale of 34.7 billion yuan, injecting strong capital momentum into the transformation of old and new kinetic energy and enhancing industrial quality and efficiency [1] Group 2 - Shandong's Vice Governor Zhang Haibo invited entrepreneurs and investors to deeply participate in Shandong's development, emphasizing the importance of focusing on industrial upgrades and technological innovation [2] - The Shandong Development and Reform Commission highlighted the event as a significant window to showcase the province's solid industrial foundation, huge investment potential, and favorable business environment, committing to a full-chain tracking service mechanism for signed funds and projects [2] - The recently introduced "Action Plan for Promoting High-Quality Development of Venture Capital in Shandong Province" aims for an annual growth of over 10% in venture capital investment by the end of 2027, with a management scale exceeding 400 billion yuan [3]

Core Insights - The announcement of a $5.6 billion licensing agreement between Rongchang Biopharma and AbbVie marks a significant milestone for Chinese innovative drugs entering the global market, indicating a shift from follower to leader in the dual antibody space [1][3] - Concurrently, Kangfang Biopharma's partner, Summit Therapeutics, submitted a Biologics License Application (BLA) for Ivoris monoclonal antibody to the FDA, further highlighting the progress of Chinese dual antibodies on the international stage [1][4] - However, the termination of a licensing agreement by Yiming Oncology with Instil Bio serves as a cautionary tale for the challenges faced by Chinese companies in global expansion [1][10] Group 1: Major Developments - Rongchang Biopharma's agreement with AbbVie includes an upfront payment of $650 million and potential milestone payments of up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [3] - Kangfang Biopharma's Ivoris monoclonal antibody is positioned to address a significant unmet clinical need in treating EGFR-mutant non-small cell lung cancer, with the FDA expected to make a decision by Q4 2026 [4][5] - The competitive landscape for PD-1/VEGF dual antibodies is intensifying, with major pharmaceutical companies increasingly focusing on a few validated "winners" in the market [2][9] Group 2: Industry Trends - The recent high-value transactions in the dual antibody space reflect a growing recognition of the clinical and commercial potential of Chinese innovative drugs, with transaction amounts reaching new heights [9] - The competitive dynamics are shifting, as the number of potential international buyers decreases due to the concentration of capital and interest in a limited number of validated products [10][13] - The success of PD-1/VEGF dual antibodies is seen as pivotal for the future of cancer treatment, with ongoing clinical trials exploring their combination with other therapies to enhance efficacy [14]

Core Viewpoint - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation declines and questionable client relationships, raising concerns about financial transparency and potential misrepresentation in disclosures [1][3][5]. Group 1: Acquisition and Valuation - Haili Biological acquired 55% of Rui Sheng Biological for 935 million yuan, valuing the company at 1.711 billion yuan, representing a 952% increase in book value [1]. - Rui Sheng Biological's valuation was subsequently revised down to 974 million yuan, reflecting a 43% drop within eight months post-acquisition due to declining performance [1][2]. Group 2: Client Relationships and Disclosures - Wuhan He Mu Medical Technology, registered in April 2023, was listed as Rui Sheng Biological's largest client for 2022, raising questions about the legitimacy of this relationship [3][4]. - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [5][6]. - A second client, Shandong Quanming Medical, initially listed as a major client, later denied any collaboration with Rui Sheng Biological, further complicating the company's client disclosure credibility [9][10][11]. Group 3: Industry Context and Performance - Rui Sheng Biological's products, particularly in the dental implant repair materials sector, had previously seen rapid growth due to favorable market conditions and increased demand post-COVID-19 [22][23]. - However, the company faced significant challenges in 2025, including a 50%-60% price drop in bone powder products and increased competition, leading to a substantial decline in revenue and profit [23][24].

Core Insights - The "Action Plan" aims for Yunnan Province to achieve an industrial output value exceeding 2 trillion yuan by 2027, with a focus on developing a modern industrial system and addressing key industry challenges [1][2]. Group 1: Industrial Development Goals - The plan sets a target for the industrial output value to surpass 2 trillion yuan by 2027, with a 3% increase in the share of non-tobacco and non-energy industries within the total industrial output [1]. - By 2030, Yunnan aims to establish itself as a significant base for clean energy, strategic non-ferrous metal industries, modern ecological agriculture, and a world-renowned tourism destination [1]. Group 2: Key Industry Focus Areas - The "Action Plan" outlines a "4+5+6" industrial development strategy, focusing on four resource-based industries (green aluminum, silicon photovoltaic, phosphorus chemical, and non-ferrous and precious metals), five advantageous industries (highland characteristic agriculture, cultural tourism, green energy, tobacco, and modern logistics), and six breakthrough areas (biomedicine, new materials, advanced equipment manufacturing, digital economy, low-altitude economy, and biomanufacturing) [2]. - Yunnan's energy sector is highlighted as a key strength, with plans to increase clean energy capacity to over 90% of total installed capacity by 2027, aiming for 180 million kilowatts of installed power by the end of 2025 [2]. Group 3: Technological and Agricultural Innovation - The plan emphasizes the integration of technological innovation with industry, focusing on enhancing strategic emerging industries and supporting biopharmaceutical development and modernization of traditional medicine [2]. - In agriculture, the strategy includes enhancing the quality and efficiency of highland characteristic agriculture through a comprehensive approach that integrates technology, sustainability, quality, and branding [2]. Group 4: Tourism Development - Yunnan is leading the initiative for "Travel and Residence in Yunnan," aiming to strengthen brand promotion and innovate product offerings to enhance its tourism appeal [3].

Group 1 - The event "Investing in Qilu for a Win-Win Future" aims to build a platform for industry and capital integration, promoting deep integration of industry, capital, innovation, and talent in Shandong Province [1] - Shandong's Vice Governor Zhang Haibo invited investors to focus on industrial upgrades and share transformation dividends during the province's transition to new growth drivers [1] - The Shandong Securities Regulatory Bureau highlighted the achievements in capital market reform and development, urging stakeholders to enhance the integration of innovation, industry, capital, and talent [1] Group 2 - The event attracted 130 investment institutions, including national funds and private equity firms, showcasing 150 quality investment projects in strategic emerging industries such as AI, high-end equipment manufacturing, and new energy materials [2] - The Shandong Securities Regulatory Bureau plans to focus on risk prevention, strong regulation, and promoting high-quality development, leveraging capital market functions to support the province's economic and social development [2]

Core Insights - The establishment of the Intellectual Property Information Service Center at Jinggangshan University aims to address the challenges faced by rural enterprises and cooperatives in Ji'an, Jiangxi Province, particularly in the biopharmaceutical sector [1][2] - The center provides comprehensive services including patent retrieval analysis, patent layout protection, and infringement risk prevention, facilitating the development of local enterprises [1] Group 1 - Ji'an is a significant hub for the biopharmaceutical industry in Jiangxi, facing issues such as a lack of specialized talent in intellectual property, insufficient core technology protection, and low patent conversion efficiency [1] - The center has formed a professional team with multidisciplinary backgrounds to support enterprises from the initial stages of technology development to market expansion [1][2] Group 2 - Since 2024, the center has assisted local companies in generating over 10 new invention patents, filling gaps in various technological fields [2] - The establishment of Jiangxi's first biopharmaceutical industry patent pool has integrated 11 core patents, covering areas such as quality variety cultivation and ecological pest control [2] - The implementation of the patent pool has led to a 50% reduction in pests and diseases in standardized planting bases, stabilizing production yields [2]

齐鲁晚报.齐鲁壹点李梦晴 市委十六届十次全会暨市委经济工作会议提出"强化创新驱动，建设更高水平创新型城市"，围绕这一目标，德州市科技局2026年将认真贯彻落实全会精 神，重点实施六大专项行动： 一是实施"技术攻关突破行动"，聚焦集成电路、生物医药、新能源新材料等重点领域，支持骨干企业牵头攻关，积极承担省级以上重大科技项目，同时自 主布局一批市级重点研发计划项目，让更多"德州造"关键产品走向高端、填补空白。 二是实施"科技创新平台提质行动"，支持龙头企业创建省级技术创新中心、重点实验室等高能级平台，加强市级平台动态管理与绩效评估，让创新平台支 撑体系服务产业发展更加紧密。 三是实施"科技型企业登高行动"，完善"科技型中小企业—高新技术企业—领军企业"梯次培育体系，分层分类精准支持，让传统产业转型升级，新兴产业 茁壮成长、未来产业破局起势。 四是实施"科技人才引育赋能行动"，鼓励企业搭建多元引才平台，让"科技副总"等人才机制持续发力，为企业科技创新提供更加有力的智力支撑。 1月14日，德州市召开德州"2025回望记"系列主题新闻发布会第二场，介绍2025年度德州科技工作成效，并回答记者提问。 五是实施"科技成果转 ...

合肥市瑶海区科技创新投资基金合伙企业（有限合伙）（以下简称"瑶海科创基金"）成立于2025 年7月，总规模20亿元，瑶海科创基金委托合肥兴泰资本管理有限公司（以下简称"管理机构"） 管理。 按照"政府引导、市场运作、协同联动、科学决策、防范风险"的运作原则，瑶海科创基金旨在引 导社会资本投向新一代信息技术（人工智能、软件、物联网）、生物医药、高端装备与新材料、新 能源（含氢能）、智能机器人（含低空经济）、生产性服务业等产业，促进合肥市瑶海区新质生产 力培育与产业集聚。现面向社会公开遴选第三批参股子基金管理机构。本次遴选范围： 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ 热文： 投资人"忙疯了" 上述领域拟设子基金采用新设子基金形式，瑶海科创基金对单支子基金的认缴出资规模原则上不超 过1.5亿元，对单支子基金认缴出资比例原则上不超过35%。单支子基金规模原则上为3-5亿元。 子基金投资应聚焦其申报领域，对申报领域的投资额原则上不得低于子基金投资额的70%。 （三）计划设立不超过2支早期硬科技类子基金，主要投资于 ...